Comparative Analysis Of Visual Outcomes With Eyhance And Puresee Intraocular Lenses Following Cataract Surgery
Published 2025 - 43rd Congress of the ESCRS
Reference: FP05.02 | Type: Free paper | DOI: 10.82333/czsm-4539
Authors: Matteo Forlini* 1
1Department of Ophthalmology,San Marino State Hospital,San Marino,San Marino
Purpose
To compare visual and refractive outcomes of two intraocular lens models (IOLs): Tecnis PureSee/PureSee toric (a new partial range of field extended (PRoF-Ex) IOL with the more established Eyhance/Eyhance toric IOL (partial range of field enhanced (PRoF-En) IOL implanted bilaterally following cataract surgery.
Setting
Optegra Eye Health Care, UK
Methods
A retrospective analysis was conducted on 157 cataract procedures (80 eyes Eyhance/Eyhance toric IOL, 77 eyes PureSee/Puresee toric IOL), targeting emmetropia in all cases. Data were collated from the electronic medical records for analysis. Postoperative uncorrected distance visual acuity (UDVA), refractive accuracy, and binocular distance and near vision were evaluated. Eyes with co-pathology and less than a weeks follow up were excluded from analysis.
Results
Postoperative monocular UDVA was significantly better in the PureSee group (p < 0.05) . Refractive accuracy (within ±1.00 D of predicted post op refraction) was comparable between groups (p>0.05). Mean binocular distance vision for the Eyhance cohort (N=40) was 0.04 ±0.09 logMAR. For PureSee, mean binocular distance vision (N=33) was -0.01 ±0.07 logMAR (p<0.05). Mean binocular near vision for Eyhance (N=27) was 0.4 ±0.14 logMAR and binocular near vision for PureSee (N=25) was 0.37 ±0.11 logMAR (p>0.05). Patient satisfaction levels were generally high in this cohort -90% of PureSee patients were satisfied with the outcomes overall and 87% of Eyhance patients reported being satisfied with their overall outcomes.
Conclusions
Both Eyhance and PureSee demonstrated good visual outcomes and refractive accuracy, with PureSee comparing favourably to Eyhance for some of the metrics assessed. Longer term evaluation of intermediate and patient reported outcomes data are underway and will be reported in due course.